Oldest Patient ‘Cured’ of HIV Still in Remission 5 Years After Transplant for AML
A 68-year-old man with HIV-1 who underwent hematopoietic cell transplant (HCT) for acute myelogenous leukemia 5 years ago has been free of HIV infection for 35 months after stopping antiretroviral treatment (ART), according to a case report. The patient received an HCT from a donor with the rare delta-32 mutation, which causes a CCR5 deletion […]
Standard Lymphoma Therapies Tied to Higher Risk for New Malignancies
Use of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) for patients with aggressive lymphoma was associated with an increased risk of certain second primary malignancies (SPMs), according to a retrospective Danish population-based cohort study. The overall SPM rate was higher among lymphoma patients compared with matched controls from the general population (HR 2.35, 95% […]
Upfront Transplant Prevails Again in Newly Diagnosed Myeloma
An immunomodulatory-free carfilzomib (Kyprolis)-based triplet regimen failed to prove non-inferior to autologous hematopoietic stem-cell transplantation (HSCT) for the upfront treatment of newly diagnosed multiple myeloma, a randomized trial from the U.K. found. The open-label phase II CARDAMON study included nearly 300 patients, with 57.7% achieving at least a very good partial response (VGPR) with the […]
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT
NEW ORLEANS — Patients who have neutropenia after undergoing hematopoietic stem cell transplantation (HSCT) do not need to restrict themselves to unpalatable hospital foods, a researcher said here. A randomized study of over 200 patients with hematologic diseases showed that patients who received a non-restrictive diet — including fresh fruits and vegetables, cold cuts, and […]
New Evidence Sheds Light on Stem Cell Transplantation for Progressive MS
Autologous hematopoietic stem cell transplantation (AHSCT) was not superior in preventing relapses or reducing disability progression than natalizumab (Tysabri) in progressive multiple sclerosis (MS), new research suggested. Patients with progressive MS, advanced disability, and low pre-treatment relapse activity who had AHSCT experienced similar on-treatment frequency of relapses as matched patients treated with natalizumab over up […]